MX2021002028A - Metodos y composiciones para farmacos para tratar enfermedades oftalmicas. - Google Patents

Metodos y composiciones para farmacos para tratar enfermedades oftalmicas.

Info

Publication number
MX2021002028A
MX2021002028A MX2021002028A MX2021002028A MX2021002028A MX 2021002028 A MX2021002028 A MX 2021002028A MX 2021002028 A MX2021002028 A MX 2021002028A MX 2021002028 A MX2021002028 A MX 2021002028A MX 2021002028 A MX2021002028 A MX 2021002028A
Authority
MX
Mexico
Prior art keywords
retinal
diseases
ocular
limitation
eye
Prior art date
Application number
MX2021002028A
Other languages
English (en)
Spanish (es)
Inventor
Scott W Cousins
Priyatham S Mettu
David M Gooden
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of MX2021002028A publication Critical patent/MX2021002028A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2021002028A 2018-08-20 2019-08-20 Metodos y composiciones para farmacos para tratar enfermedades oftalmicas. MX2021002028A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862719938P 2018-08-20 2018-08-20
PCT/US2019/047309 WO2020041344A1 (en) 2018-08-20 2019-08-20 Methods and compositions for drugs to treat ophthalmic diseases

Publications (1)

Publication Number Publication Date
MX2021002028A true MX2021002028A (es) 2021-07-21

Family

ID=69591159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002028A MX2021002028A (es) 2018-08-20 2019-08-20 Metodos y composiciones para farmacos para tratar enfermedades oftalmicas.

Country Status (14)

Country Link
US (2) US12221447B2 (cg-RX-API-DMAC7.html)
EP (1) EP3840745A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021534202A (cg-RX-API-DMAC7.html)
KR (1) KR20210049857A (cg-RX-API-DMAC7.html)
CN (1) CN112654353A (cg-RX-API-DMAC7.html)
AU (1) AU2019326448A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003189A2 (cg-RX-API-DMAC7.html)
CA (1) CA3109809A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003607A2 (cg-RX-API-DMAC7.html)
IL (1) IL280952A (cg-RX-API-DMAC7.html)
MX (1) MX2021002028A (cg-RX-API-DMAC7.html)
SG (1) SG11202101522WA (cg-RX-API-DMAC7.html)
TW (1) TW202021968A (cg-RX-API-DMAC7.html)
WO (1) WO2020041344A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003189A2 (pt) 2018-08-20 2021-05-11 Duke University métodos e composições de fármacos para tratar doenças oftálmicas
WO2024257328A1 (ja) * 2023-06-16 2024-12-19 千寿製薬株式会社 眼疾患モデル動物
JP7776899B1 (ja) 2024-06-14 2025-11-27 株式会社坪田ラボ 局所投与用の重症眼表面疾患の処置剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4153693B2 (ja) * 2001-04-25 2008-09-24 大日本住友製薬株式会社 新規なCaMKK阻害剤
GB0600764D0 (en) * 2006-01-13 2006-02-22 Crysoptix Ltd Organic compound, optical crystal film and method of production thereof
GB0600763D0 (en) * 2006-01-13 2006-02-22 Crysoptix Ltd 6, 7-dihydrobenzimidazo[1,2-C]quininazolin-6-one carboxylic acid, its esters and method of synthesis thereof
US8207185B2 (en) 2006-10-12 2012-06-26 Duke University CaMKKβ as a target for treating obesity
JP5464395B2 (ja) 2008-02-01 2014-04-09 大陽日酸株式会社 重水素化された芳香環又は複素環を有する化合物の製造方法
WO2009154754A2 (en) 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
EP2334621A1 (en) 2008-09-16 2011-06-22 Concert Pharmaceuticals, Inc. Deuterated 2-amino-3-hydroxypropanoic acid derivatives
US20130253035A1 (en) 2010-08-16 2013-09-26 Duke University Camkk-beta as a target for treating cancer
EP2638126B1 (en) * 2010-11-09 2015-02-18 Crysoptix K.K. Negative dispersion retardation plate and achromatic circular polarizer
SG194625A1 (en) 2011-05-23 2013-12-30 Sanofi Sa Process for the preparation of deuterated compounds containing n-alkyl groups
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. 小胞モノアミン輸送体2の重水素化ベンゾキノリン阻害剤の製剤薬物動態
AU2013361320A1 (en) 2012-12-20 2015-07-02 Concert Pharmaceuticals, Inc. Deuterated ALK inhibitors
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
BR112021003189A2 (pt) 2018-08-20 2021-05-11 Duke University métodos e composições de fármacos para tratar doenças oftálmicas

Also Published As

Publication number Publication date
IL280952A (en) 2021-04-29
WO2020041344A1 (en) 2020-02-27
CN112654353A (zh) 2021-04-13
EP3840745A4 (en) 2022-06-08
WO2020041344A4 (en) 2020-03-26
AU2019326448A1 (en) 2021-03-11
CO2021003607A2 (es) 2021-07-30
BR112021003189A2 (pt) 2021-05-11
US20210198266A1 (en) 2021-07-01
KR20210049857A (ko) 2021-05-06
TW202021968A (zh) 2020-06-16
SG11202101522WA (en) 2021-03-30
US12221447B2 (en) 2025-02-11
US20250122209A1 (en) 2025-04-17
EP3840745A1 (en) 2021-06-30
JP2021534202A (ja) 2021-12-09
CA3109809A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
RU2009145939A (ru) Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
CA2806942C (en) Compounds for the treatment/prevention of ocular inflammatory diseases
RU2014123472A (ru) Производные 4-прегенен-11ss-17-21-триол-3,20-диона для лечения глазных болезней
PH12020551766A1 (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
CO2021003607A2 (es) Métodos y composiciones para medicamentos para tratar enfermedades oftálmicas
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
WO2010010702A1 (ja) 軸性近視の予防または治療剤
MX2021005352A (es) Tratamiento y diagnóstico de enfermedades oculares mediadas por autoanticuerpos.
JP2016522830A5 (cg-RX-API-DMAC7.html)
JP2017500340A5 (cg-RX-API-DMAC7.html)
JP2013513606A5 (cg-RX-API-DMAC7.html)
RU2003124369A (ru) Способ лечения макулярного разрыва
CN108348516B (zh) 外用剂
JPWO2024257328A5 (cg-RX-API-DMAC7.html)
CA2817505C (en) Pharmaceutical formulation having neuroprotective activity
RU2014106328A (ru) Фармацевтические композиции, содержащие 4-бром-n-(имидазолидин-2-илиден)-1н-бензимидазол-5-амин для лечения заболеваний сетчатки
Uno Ocular Mycosis.
MD870Y (en) Method for treating senile cataract
US20180221417A1 (en) Treatment of dry eye using amnion released factors
JP2013523892A (ja) 視覚障害を処置するための組成物および方法
MA53146B1 (fr) Procédé de préparation de suspensions aqueuses ophtalmiques stériles de nanocristaux de forme a de propionate de fluticasone
RU2706338C1 (ru) Способ лечения передних увеитов животных и птиц тяжелой степени тяжести
Wi et al. A Case of Persistent Shallow Anterior Chamber in Glaucoma Drainage Device Implantation Recovered by Fibrin Glue
RU2004109541A (ru) Способ лечения птеригиума на основе аутопластики
MD978Y (ro) Metodă de tratament al cataractei senile